An Innovative PN HPT™-based Medical Device for the Therapy of Deteriorated Periocular Skin Quality

Abstract

Objective: Polynucleotides Highly Purified Technology (PN HPT™) hydrate the extracellular matrix and fill the depressed dermal spaces in the periocular areas with skin quality problems; moreover, PN HPT™ replenish the nucleotide precursor pool. Within a long-term monitoring program, the questionnaire-based survey aimed to confirm the profile of known side effects and contraindications. Methods: Survey base: A real-world cohort of 48 ambulatory outpatients with periocular skin quality problems after a three-session intradermal injection cycle with 15 mg of PN HPT™- based gel in disposable syringes PLINEST eye, Mastelli S.r.l., Sanremo, Italy). Study purpose: Confirming the PN HPT™ persisting efficacy and safety in improving facial and periocular skin quality and texture. Assessment tools: Investigator-assessed Wrinkle Severity Rating Scale (WSRS) and investigator- and subject assessed Global Aesthetic Improvement Scale (GAIS) at baseline and four weeks after the last PN HPT™ intradermal injection. Results: The mean whole-cohort WSRS score improved from 3.3 ± 0.93 at baseline to 1.8 ± 0.90 at the final follow up visit (–45.5%, p<0.0001), including in the 39 cohort outpatients with hypotrophic skin (–46.9%, p<0.0001). According to investigators, 87.5% of cohort subjects and outpatients were GAIS responders, with 50% “Much improved” or “Very much improved”. “Much improved” and “Very much improved” were the self-assessed GAIS ratings for 56.3% of surveyed subjects. Limitations: Brief overall follow-up, lack of a control group. Conclusion: PN HPT™ retain the usual excellent value and safety in improving skin quality in the periocular region with no variations over time and no differences in subjects with correctly structured or hypotrophic skin.